Company intelligence / Profile preview

PaxVax Berna

Redwood City, California, USA

Ownership: Private
Employees: ~250
Development stage: Other

Overview

PaxVax was a specialty vaccine company focused on the development and commercialization of vaccines for infectious diseases, particularly in the travel health market. The company's primary products included Vivotif, an oral typhoid vaccine, and Vaxchora, the only FDA-approved vaccine against cholera. PaxVax maintained a significant presence in Bern, Switzerland, following its acquisition of the Berna Biotech manufacturing site from Crucell in 2014. In 2018, PaxVax was acquired by Emergent BioSolutions for $270 million, integrating its portfolio into Emergent's travel health business.

Therapeutic areas: Infectious Diseases
Modalities: Vaccine
Industry: Biotech

Partnerships

US Department of Defense

Beyond the preview

Go deeper on PaxVax Berna.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PaxVax Berna.

Explore the full profile